Table 2. Characteristics of 12 case-control studies on miR-499 and miR-149.
| Author | Year | Ethnicity | Cancer type | Control source | Genotyping method | SNP | Case /Control | HWE of control | Quality score |
|---|---|---|---|---|---|---|---|---|---|
| Xiang | 2012 | Asian | HCC | HB | PCR-RFLP | rs3746444 | 100/100 | 0.28 | 10 |
| Zhou | 2012 | Asian | HCC | HB | PCR-RFLP | rs3746444 | 186/483 | 0.10 | 14 |
| Kim | 2012 | Asian | HCC | PB | PCR-RFLP | rs3746444 | 159/201 | 0.27 | 13 |
| PB | PCR-RFLP | rs2292832 | 159/201 | 0.34 | 13 | ||||
| Akkiz | 2011 | Caucasian | HCC | HB | PCR-RFLP | rs3746444 | 222/222 | 0.03 | 13 |
| Ahn | 2012 | Asian | GC | PB | PCR-RFLP | rs3746444 | 461/447 | 0.82 | 13 |
| PB | PCR-RFLP | rs2292832 | 461/447 | 0.97 | 13 | ||||
| Okubo | 2010 | Asian | GC | HB | PCR-RFLP | rs3746444 | 552/697 | 0.04 | 9 |
| Vinci | 2012 | Caucasian | CRC | NR | HRMA | rs3746444 | 160/178 | 0.02 | 10 |
| NR | HRMA | rs2292832 | 160/178 | 0.91 | 13 | ||||
| Min | 2011 | Asian | CRC | PB | PCR-RFLP | rs3746444 | 446/502 | 0.45 | 14 |
| PB | PCR-RFLP | rs2292832 | 446/502 | 0.95 | 14 | ||||
| Srivastava | 2010 | Asian | GBC | PB | PCR-RFLP | rs3746444 | 230/230 | 0.56 | 15 |
| Chu | 2012 | Asian | OSCC | HB | PCR-RFLP | rs3746444 | 470/425 | 0.97 | 11 |
| HB | PCR-RFLP | rs2292832 | 470/425 | <0.01 | 8 | ||||
| Umar | 2012 | Asian | ESCC | PB | PCR-RFLP | rs3746444 | 289/309 | 0.08 | 13 |
| Zhang | 2012 | Asian | CRC | NR | PCR-RFLP | rs2292832 | 435/443 | 0.58 | 13 |
| GC | NR | PCR-RFLP | rs2292832 | 274/269 | 0.69 | 13 |
CRC: colorectal cancer; ESCC: esophageal squamous cell carcinoma; GBC: gallbladder cancer; GC: gastric cancer; HCC: hepatocellular cancer; OSCC: oral cavity squamous cancer; HWE: Hardy-Weinberg equilibrium in control groups; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; HRMA: high-resolution melting analysis; HB: hospital based; PB: population based; NR: not reported.